CAJ | 학술논문

目的观察沙格雷酯在颈动脉内膜剥脱术(carotid endarterectomy,CEA)后抗血小板治疗效果和安全性.方法回顾性分析宣武医院血管外科2008年10月至2011年2月收治的接受CEA治疗的64例患者的临床资料.根据术后抗血小板用药情况,将患者分为阿司匹林联合氯吡格雷组(A组,阿司匹林100 mg/d联合氯吡格雷50 mg/d)和沙格雷酯联合氯吡格雷组(B组,沙格雷酯100 mg,3次/d联合氯吡格雷50 mg/d),比较术后新发脑卒中、再狭窄、出血事件的发生率和死亡率.结果 A组34例,B组30例,其中新发脑卒中1例(B组),患侧颈动脉再狭窄3例(中度再狭窄A组1例,B组2例,重度再狭窄A组1例),出血事件3例(一般出血事件A组3例,其中皮下淤血2例,肉眼血尿1例).2组均无死亡病例.新发脑卒中和再狭窄发生率及出血事件发生率2组均较低,组间差异无统计学意义.结论在术后新发脑卒中、再狭窄发生率、死亡率和出血事件发生率方面,阿司匹林和沙格雷酯并无明显差异.沙格雷酯联合氯吡格雷用于CEA术后抗血小板治疗是安全有效的.
목적 관찰사격뢰지재경동맥내막박탈술(carotid endarterectomy,CEA)후항혈소판치료효과화안전성.방법 회고성분석선무의원혈관외과2008년10월지2011년2월수치적접수CEA치료적64례환자적림상자료.근거술후항혈소판용약정황,장환자분위아사필림연합록필격뢰조(A조,아사필림100 mg/d연합록필격뢰50 mg/d)화사격뢰지연합록필격뢰조(B조,사격뢰지100 mg,3차/d연합록필격뢰50 mg/d),비교술후신발뇌졸중、재협착、출혈사건적발생솔화사망솔.결과 A조34례,B조30례,기중신발뇌졸중1례(B조),환측경동맥재협착3례(중도재협착A조1례,B조2례,중도재협착A조1례),출혈사건3례(일반출혈사건A조3례,기중피하어혈2례,육안혈뇨1례).2조균무사망병례.신발뇌졸중화재협착발생솔급출혈사건발생솔2조균교저,조간차이무통계학의의.결론 재술후신발뇌졸중、재협착발생솔、사망솔화출혈사건발생솔방면,아사필림화사격뢰지병무명현차이.사격뢰지연합록필격뢰용우CEA술후항혈소판치료시안전유효적.
Objective To observe the effectiveness and safety of Sarpogrelate as antiplatelet therapy in carotid endarterectomy (CEA) cases.Methods We retrospectively analyzed the clinical data of 64 CEA cases collected from October 2008 to February 2011 at Xuanwu Hospital.According to postoperative antiplatelet medication patients were divided into aspirin combined Clopidogrel group (group A,aspirin 100 mg/d; Clopidogrel 50 mg/d) and Sarpogrelate combined Clopidogrel group (group B,Sarpogrelate 100 mg,tid; Clopidogrel 50 mg/d).Postoperative new stroke,restenosis,bleeding and mortality were compared between groups.Results There were 34 cases in group A and 30 cases in group B.New stroke (one case) (in group B),ipsilateral carotid restenosis (moderate:1 case in group A,2 cases in group B;severe:1 case in group A),bleeding episode (general bleeding event:3 cases in group A including hypodermic gore in 2 cases,gross hematuria in 1 case).There was no death.There was no significant differences between two groups in new stroke,bleeding and restenosis.Conclusions Sarpogrelate combined with Clopidogrel for antiplatelet therapy after CEA was safe and effective.